In a nutshell This study evaluated isatuximab, pomalidomide (Imnovid) and dexamethasone (Decadron) for recurrent or non-responsive multiple myeloma (MM). This study concluded that this treatment combination was safe and effective for these patients. Some background There are several treatment options for patients with MM. Most initial...
Read MoreCurrent treatment status-Undergoing active treatment Posts on Medivizor
Evaluating scoring systems used to predict outcomes for patients with advanced HL
In a nutshell This study compared the effectiveness of the International Prognostic Scoring System (IPSS) measuring 7 factors (IPSS7) versus the IPSS measuring 3 factors (IPSS3) in predicting outcomes for patients with Hodgkin's lymphoma (HL). This study concluded that there was no significant difference between these scoring systems. Some...
Read MoreReviewing treatment strategies for early-stage Hodgkin lymphoma
In a nutshell This article reviews treatment strategies for patients with early-stage (stage 1 – 2) Hodgkin lymphoma (HL). Some background One of the main treatment goals for patients with HL is to improve long-term outcomes. However, many patients experience complications decades after initial treatment. These may include secondary cancer...
Read MoreCan molecular monitoring help treatment and outcomes in patients with chronic myeloid leukemia?
In a nutshell This study looked at the use of molecular monitoring to assess outcomes in patients with chronic myeloid leukemia. Researchers found that molecular monitoring at 3 and 12 months is beneficial to these patients. Some background Chronic myeloid leukemia (CML) is a cancer of the bone marrow. This leads to an abnormal immune system and...
Read MoreRisk of hepatitis B reactivation in patients with lymphomas receiving obinutuzumab or rituximab
In a nutshell This study looked at the risk of reactivating hepatitis B (HBV) infection in patients with lymphoma treated with obinutuzumab (Gazyva) or rituximab (Rituxan). Researchers found that HBV infection was reactivated in some of these patients but treatment options are available. Some background Lymphoma is a cancer of the immune system....
Read MoreEvaluating the impact of early PET/CT scanning on survival in patients with lymphoma after stem cell transplant
In a nutshell This study evaluated the impact of early FDG PET/CT scanning on the survival of patients with lymphoma after allogeneic stem cell transplantation (alloSCT). This study concluded that having positive scan results at 3 months after alloSCT may highly predict relapse and poor survival in these patients. Some background An alloSCT is a...
Read MoreEvaluating the impact of early PET/CT scanning on survival in patients with lymphoma after stem cell transplant
In a nutshell This study evaluated the impact of early FDG PET/CT scanning on the survival of patients with lymphoma after allogeneic stem cell transplantation (alloSCT). This study concluded that having positive scan results at 3 months after alloSCT may highly predict relapse and poor survival in these patients. Some background An alloSCT is a...
Read MoreEvaluating the impact of early PET/CT scanning on survival in patients with lymphoma after stem cell transplant
In a nutshell This study evaluated the impact of early FDG PET/CT scanning on the survival of patients with lymphoma after allogeneic stem cell transplantation (alloSCT). This study concluded that having positive scan results at 3 months after alloSCT may highly predict relapse and poor survival in these patients. Some background An alloSCT is a...
Read MoreRe-treatment with cetuximab improves cancer outcomes in patients with inoperable colorectal cancer
In a nutshell This study investigated the effect of cetuximab (Erbitux) in patients with metastatic (spread to other parts of the body) colorectal cancer who did not respond to initial cetuximab treatment. Researchers suggested that this treatment may be beneficial in longer treatment durations. Some background The standard treatment for patients...
Read MoreLong term results discussing radiotherapy and hormone therapy treatments for patients with prostate cancer
In a nutshell This study aimed to evaluate whole pelvic radiotherapy (WPRT) compared to prostate only radiotherapy (PORT) with hormonal therapy (HT) before or after radiation for patients with intermediate- or high-risk prostate cancer. This study found that HT before radiotherapy and WPRT had superior long-term survival without cancer growing or...
Read MoreThe effect of ibrutinib on white blood cell count in CLL
In a nutshell This study wanted to look at the effect of ibrutinib (Imbruvica) on white cell count (immune cells) in patients with chronic lymphocytic leukemia. Researchers found that increases in white cell count during ibrutinib treatment were normal and did not indicate poor outcomes in these patients. Some background Chronic lymphocytic leukemia...
Read MoreEvaluating outcomes after radiotherapy and PET/CT scanning for patients with follicular lymphoma
In a nutshell This study evaluated the outcomes of patients with localized (cancer has not spread to other parts of the body) early-stage follicular lymphoma (FL) after positron emission tomography/computed tomography (PET/CT) scanning. This study concluded that radiotherapy is a highly effective treatment for these patients. Some background FL is one...
Read More